Autonomix Medical to Present Final Pancreatic Cancer Pain Study at SIO 2026
Event summary
- Autonomix Medical will present final clinical data on transvascular RF ablation for pancreatic cancer pain mitigation at SIO 2026 Annual Scientific Meeting on February 6, 2026.
- The ePoster presentation (Abstract #327) will be delivered by Clarke Wilkirson, PhD during the Science and Sips Reception.
- Autonomix's technology aims to address a significant unmet clinical need in pain management for pancreatic cancer patients.
- The company's platform technology includes a catheter-based microchip sensing array for neural signal detection.
The big picture
Autonomix Medical's presentation at SIO 2026 highlights the growing focus on minimally invasive, image-guided therapies for cancer care. The company's transvascular RF ablation technology represents a potential breakthrough in pain management for pancreatic cancer, a condition with limited treatment options. The strategic significance lies in Autonomix's ability to address a critical unmet need, positioning itself as a key player in the interventional oncology space.
What we're watching
- Clinical Efficacy
- How the final analysis will impact the perceived effectiveness of Autonomix's transvascular RF ablation approach in pain mitigation.
- Market Adoption
- Whether the positive clinical data will accelerate regulatory approval and commercialization of the technology.
- Platform Expansion
- The pace at which Autonomix can leverage its platform technology for other indications beyond pancreatic cancer.
Related topics